On the statistical accuracy of biomarker assays for HIV incidence

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 4, 2010, Pages 406-414

  Brookmeyer, Ron ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BED; biomarker; epidemiology; incidence; statistics

Indexed keywords

BIOLOGICAL MARKER;

ACCURACY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; PROBABILITY; STATISTICAL ANALYSIS; VARIANCE; ANALYSIS OF VARIANCE; BIOSTATISTICS; CROSS-SECTIONAL STUDY; OBSERVER VARIATION; REPRODUCIBILITY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANALYSIS OF VARIANCE; BIOSTATISTICS; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; OBSERVER VARIATION; PROBABILITY; REPRODUCIBILITY OF RESULTS;

EID: 77955481769     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181dc6d2c     Document Type: Article

References (27)

1. Le Vu S, Pillonel J, Semaille C, et al. Principles and uses of HIV incidence estimation from recent infection testing-A review. Eurosurveillance. 2008;13:11-16.
2. Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross sectional survey using early diagnostic tests. Am J Epidemiol. 1995;141:166-172.
3. Janssen RS, Satten GA, Stramer S, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280:42-48.
4. Murphy G, Parry JV. Assays for the detection of recent infections with Human Immunodeficiency Virus Type 1. Eurosurveillance. 2008;13: 4-10.
5. Parekh BS, Kennedy MS, Dobbs T, et al. Quantitative detection of increasing HIV Type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses. 2002;18:295-307.
6. UNAIDS Reference Group for Estimates, Modeling and Projections. Statement on the Use of the BED-assay for the Estimation of HIV-1 Incidence for Surveillance or Epidemic Monitoring. Report of a meeting of the UNAIDS Reference Group for Estimates, Modeling and Projections. Athens, Greece. Geneva, Switzerland: UNAIDS; Available at: http://www.epidem.org/Publications/ BED%20statement.pdf. Accessed December 13-15, 2005.
7. Karita E, Price M, Hunter E, et al. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS. 2007;21:403-408.
8. Hargrove JW, Humphrey JH, Mutasa K, et al. Improved HIV-1 incidence estimates using BED capture enzyme immunoassay. AIDS. 2008;22: 511-518.
9. McDougal JS, Parekh BS, Peterson ML, et al. Comparison of HIV-1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses. 2006;22:945-952.
10. McWalter TA, Welte A. Relating recent infection prevalence to incidence with a subpopulation of nonprogressors. J Math Bio. 2009;DOI 10.1007/s00285-009-0282-287
11. McWalter TA, Welte A. A comparison of biomarker based incidence estimators. PLoS ONE. 2009;4(10):e7368.
12. Brookmeyer R. Should biomarker estimates of HIV incidence be adjusted? AIDS. 2009;23:485-491.
13. Hargrove JW. BED estimates of HIV incidence must be adjusted. AIDS. 2009;23:2064-2065.
14. McDougal JS. BED estimates of HIV incidence must be adjusted. AIDS. 2009;23:2064-2065.
15. Welte A, McWalter TA, Barnighausen T. Reply to "Should biomarker estimates of HIV incidence be adjusted?" AIDS. 2009;23:2062-2063.
16. Brookmeyer R. Response to correspondence on "Should biomarker estimates of HIV incidence be adjusted?" AIDS. 2009;23:2066-2068.
17. Wang R, Lagakos SW. On the use of adjusted cross-sectional estimators of HIV incidence. J Acquir Immune Defic Syndr. 2009;52:538-547.
18. Using the BED HIV-1 Capture EIA Assay to estimate incidence using STARHS in the context of surveillance in the United States, October 2007. Centers for Disease Control and Prevention website. Available at: http:/www.cdc.gov/hiv/ topics/surveillance/resources/factsheets/BED.htm. Accessed March 5 2010.
19. Kaplan E, Brookmeyer R. "Snapshot estimators of recent HIV incidence rates." Oper Res. 1999;47:29-37.
20. Cox DR. Renewal Theory. London, United Kingdom: Methuen and Co. Ltd; 1962.
21. Laeyendecker O, Rothman RE, Henson C, et al. The effect of viral suppression on cross-sectional incidence testing in the Johns Hopkins Hospital Emergency Department. J Acquir Immune Defic Syndr. 2008;48: 211-215.
22. Laeyendecker O, Redd AD, Lutalo T, et al. Frequency of long-term nonprogressors in HIV-1 seroconverters from Rakai Uganda. J Acquir Immune Defic Syndr. 2009;52:316-319.
23. Okulicz O, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers and long term non-progressors in the US Department of defense HIV natural history study. J Infect Dis. 2009; 1714-1723.
24. AAlen O, Farewell VT, DeAngelis D, et al. A Markov model for HIV disease progression including the effect of HIV diagnosis and treatment; application to AIDS prediction in England and Wales. Stat Med. 1997;16: 2191-2210.
25. Mastro TD, Kim A, Hallett T, et al. Estimating HIV incidence in populations: issues, challenges and the way forward. J HIV/AIDS Surveill Epidemiol. 2010; (in press).
26. Brookmeyer R. Accounting for follow-up bias in estimation of Human Immunodeficiency virus incidence rates. J R Stat Soc A. 1997;160: 127-140.
27. Cole SR, Chu R, Brookmeyer R. Confidence intervals for biomarker-based Human Immunodeficiency Virus incidence estimates and differences using prevalent data. Am J Epidemiol. 2007;165:94-100.